Most available studies are underpowered, short-term, and heterogeneous in design, making it difficult to draw firm conclusions about long-term efficacy, optimal dosing strategies, or the specific patient subgroups most likely to benefit
Until then, the idea that GLP-1 drugs lower cancer risk is a hypothesis worth testing but not a conclusion to act on
109 RinninellaE.RaoulP.CintoniM.FranceschiF.MiggianoG
Since previous studies have linked the activation of NRF2 with the repression of lipogenic gene expression 64 , we reasoned that GSH depletion causes oxidation and consequent inactivation of KEAP1 (a repressor of NRF2), thus leading to increased antioxidant and decreased lipogenic gene expression
It means that the goal of your taper should not just be minimizing weight regain but specifically keeping regain below that 25% threshold where the health benefits start to unravel
100 , E871E875 (2015)